Abstract Background: myocardial bridging (MB) may represent a cause of myocardial ischemia in patients with non-obstructive coronary artery disease (NOCAD). Herein, we assessed the interplay
Abstract Objectives: The aim of this study was to define predictors of prosthesis-patient mismatch (PPM) and its impact on mortality after transcatheter aortic valve replacement
Abstract Background: Women represent an increasing percentage of interventional cardiologists in Italy compared with other countries. However, gaps exist in understanding and adapting to the
Abstract Aims: After percutaneous coronary intervention (PCI) with second-generation drug-eluting stent (DES), whether short dual antiplatelet therapy (DAPT) followed by single antiplatelet therapy (SAPT) with
Abstract Objectives The aims of this study were to investigate the feasibility of coronary ostia cannulation after transcatheter aortic valve replacement (TAVR) and to assess
Abstract Objective: Mitral annular disjunction (MAD) is an abnormality linked to mitral valve prolapse (MVP), possibly associated with malignant ventricular arrhythmias. We assessed the agreement
Abstract Aims: The adoption of percutaneous stellate ganglion blockade for the treatment of drug-refractory electrical storm (ES) has been increasingly reported; however, the time of
Abstract Background: There is no consensus on the benefit of red blood cell (RBC) transfusion after transcatheter aortic valve replacement. Methods: The multicenter Transfusion Requirements
Abstract Aims: The CLIMA study, on the relationship between coronary plaque morphology of the left anterior descending artery and twelve months clinical outcome, was designed
Abstract Aims: The Italian Society of Interventional Cardiology (GIse) registry Of Transcatheter treatment of mitral valve regurgitaTiOn (GIOTTO) was conceived in order to assess the
Dalla letteratura internazionale, Editoriale
visite: 10613
visite: 10450
Dalla letteratura internazionale, Editoriale
visite: 10395
Supplemento a “HEALTH TALKS” testata di informazione tecnica e professionale in medicina, in corso di registrazione presso il Tribunale di Milano, direttore responsabile: Massimiliano Melis.
©️2021 tutti i diritti e utilizzi riservati.
HEALTH&LIFE S.r.l., Milano, viale Gorizia 22, codice fiscale – P. IVA 07382900962, REA MI-1954869 e-mail staff@cnc-group.it.
HEALTH&LIFE è un’azienda parte di CnC GROUP. Le aziende parte di CnC GROUP sono sottoposte all’attività di direzione e coordinamento di CnC S.r.l. HEALTH&LIFE si impegna a fornire servizi di Qualità, aggiungendo valore alla comunicazione dei propri Clienti e trasmettendo questo valore ai loro Interlocutori: legga il nostro impegno per la Qualità su www.cnc-group.it/qualitaHn
